Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. DLBCL is a heterogeneous disease and to better characterize the molecular mechanisms and to identify new candidate cancer genes, we performed the genome-wide DNA profiles of 166 DLBCL samples uniformly treated with R-CHOP. We evaluated the impact of recurrent aberrations on the clinical outcome of DLBCL patients and we then performed unsupervised clustering to identify biological subgroups according to the genetic features. Indeed, genomic profiling of samples, identified genetic aberrations and clusters, associated with a distinct outcome in DLBCL patients. We also identified a new gain, occurring at 11q24.3, containing two transcription factors, ETS1 and FLI1. We then provided experimental data indicating a role of the two genes in DLBCL pathogenesis.